REBISMART, the first electronic
injection device for the treatment
of multiple sclerosis, has been
approved for use in Australia and
will be available on the
Pharmaceutical Benefits Scheme
from 01 May.
The device includes an interactive
screen on the electronic injector
which guides patients through a
three step process with text and
pictures, to deliver a new multi-dose
presentation of Rebif (interferon
beta-1a).The above article was sent to subscribers in Pharmacy Daily's issue from 28 Apr 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Apr 10
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.